Promising cancer combo trial halted early – no clear answers yet

NCT ID NCT05061420

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a new drug called SAR444245 combined with either pembrolizumab or cetuximab in 59 adults with head and neck cancer that had spread or come back. The goal was to see if the combinations could shrink tumors. However, the study was terminated early, so we don't have enough information to know if the treatments work or are safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR444245 (THOR-707) combined with pembrolizumab or cetuximab
What this could lead to: If it had worked, this could have pointed toward a new treatment option for head and neck cancer that doesn't respond to standard therapy.
What could go wrong: The study was terminated early, so we don't have enough data to know if the combination is effective or safe. Early-phase trials often fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

Contacts and locations

Locations

City of Hope- Site Number : 8400007

Duarte, California, 91010, United States
Investigational Site Number : 0320001

Buenos Aires, 1012, Argentina
Investigational Site Number : 1240001

Montreal, Quebec, H4A 3J1, Canada
Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, 8420383, Chile
Investigational Site Number : 1520002

Temuco, 4800827, Chile
Investigational Site Number : 1520003

Santiago, Reg Metropolitana de Santiago, 7500921, Chile
Investigational Site Number : 1520004

Viña del Mar, Valparaiso, 2540488, Chile
Investigational Site Number : 1580003

Tainan, 704, Taiwan
Investigational Site Number : 2500001

Villejuif, 94800, France
Investigational Site Number : 2500002

Strasbourg, 67033, France
Investigational Site Number : 2500003

Bordeaux, 33075, France
Investigational Site Number : 2500006

Paris, 75015, France
Investigational Site Number : 2500008

Lyon, 69008, France
Investigational Site Number : 2760004

Berlin, 12200, Germany
Investigational Site Number : 3800003

Brescia, 25123, Italy
Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, 06351, South Korea
Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, 05505, South Korea
Investigational Site Number : 5280001

Nijmegen, 6500 HB, Netherlands
Investigational Site Number : 5280002

Amsterdam, 1066, Netherlands
Investigational Site Number : 7240001

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7240003

Madrid, Madrid, Comunidad de, 28046, Spain
Investigational Site Number : 7240004

Barcelona, Barcelona [Barcelona], 08036, Spain
Investigational Site Number : 7240005

Madrid, Madrid, Comunidad de, 28040, Spain
Seattle Cancer Care Alliance Site Number : 8400006

Seattle, Washington, 98115, United States
Thomas Jefferson University Hospital Site Number : 8400003

Philadelphia, Pennsylvania, 19107, United States
University of Colorado- Site Number : 8400004

Aurora, Colorado, 80045, United States
University of Michigan- Site Number : 8400008

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.